Plain-English translation of NCT06350110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called CD19/BCMA-CAR T cells for people with severe lupus that hasn't responded to standard medications. The treatment works by collecting your own immune cells, engineering them in the laboratory to target and eliminate the abnormal B cells that cause lupus, and then infusing them back into your body. The goal is to help your immune system reset and work normally again, potentially allowing some patients to live without daily lupus medications.
Lupus is an autoimmune disease where the body attacks itself, and many patients don't get better with conventional treatments like steroids and immunosuppressive drugs. This medication represents a promising new strategy that attempts to permanently fix the root cause of lupus by eliminating the faulty immune cells responsible for the disease, rather than just managing symptoms.
You likely qualify if…
You likely don't qualify if…
First, you will undergo chemotherapy medications given intravenously for a few days to prepare your body. Then you will receive infusions of the engineered immune cells through an IV over 10-20 minutes on day zero. If you respond well to the first infusion without serious side effects and there are enough cells available, you may receive up to two or three additional infusions. You will need to attend regular follow-up visits to monitor your response and safety, and agree to use effective contraception for at least one year after treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China